AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer [PDF]
BMC Cancer, 2022 Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC).
Mari Iida +10 more
doaj +3 more sources
CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b [PDF]
Cell Death and Disease, 2023 Currently the clinical efficacy of colorectal cancer (CRC) which is the most common malignant tumors over the world has not reached an ideal level.
Qi Zhang +12 more
doaj +3 more sources
Targeting FABP4/UCP2 axis to overcome cetuximab resistance in obesity-driven CRC with drug-tolerant persister cells [PDF]
Translational OncologyColorectal cancer (CRC) is closely linked to obesity, a condition that significantly impacts tumor progression and therapeutic resistance. Although cetuximab, an EGFR-targeting monoclonal antibody, is a cornerstone in metastatic CRC treatment, resistance
Yi-Chiao Cheng +7 more
doaj +3 more sources
Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines [PDF]
Cells, 2022 Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of cetuximab response are known for HNSCC.
Izabela N. F. Gomes +11 more
doaj +3 more sources
CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration [PDF]
Biology DirectEpidermal growth factor receptor (EGFR)-targeted therapy is an important treatment for RAS wild-type metastatic colorectal cancer (mCRC), but the resistance mechanism remains unclear.
Yiting Geng +8 more
doaj +3 more sources
Multivalent Rhamnose‐Modified EGFR‐Targeting Nanobody Gains Enhanced Innate Fc Effector Immunity and Overcomes Cetuximab Resistance via Recruitment of Endogenous Antibodies [PDF]
Advanced ScienceCetuximab resistance is a significant challenge in cancer treatment, requiring the development of novel therapeutic strategies. In this study, a series of multivalent rhamnose (Rha)‐modified nanobody conjugates are synthesized and their antitumor ...
Yanchun Li +7 more
doaj +3 more sources
Stress‐induced Rab11a‐exosomes induce amphiregulin‐mediated cetuximab resistance in colorectal cancer [PDF]
Journal of Extracellular VesiclesExosomes are secreted vesicles made intracellularly in the endosomal system. We have previously shown that exosomes are not only made in late endosomes, but also in recycling endosomes marked by the monomeric G‐protein Rab11a.
John D. Mason +8 more
doaj +3 more sources
Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. [PDF]
PLoS ONE, 2020 The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC).
Rachel A O'Keefe +4 more
doaj +3 more sources
Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma [PDF]
Cancer Biology & Medicine, 2020 Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally ...
Olivia Leblanc +14 more
doaj +3 more sources
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity. [PDF]
Cancer Drug Resist, 2023 Aim: Acquired resistance to the targeted agent cetuximab poses a significant challenge in finding effective anti-cancer treatments for head and neck squamous cell carcinoma (HNSCC).
Zaryouh H +14 more
europepmc +2 more sources